Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors

Endocrine-Related Cancer

Volumn 18, Issue 4, 2011, Pages 439-450

  Molè, Daniela ^a   Gagliano, Teresa ^a   Gentilin, Erica ^a   Tagliati, Federico ^a   Pasquali, Claudio ^b   Ambrosio, Maria Rosaria ^a   Pansini, Giancarlo ^a   Degli Uberti, Ettore C ^a   Zatelli, Maria Chiara ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; ENZASTAURIN; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE C; RECOMBINANT SOMATOMEDIN C;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SECRETION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; INCUBATION TIME; INSULIN RELEASE; OUTCOME ASSESSMENT; PANCREAS ISLET CELL TUMOR; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INDOLES; INSULIN; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTEIN KINASE C; TUMOR CELLS, CULTURED;

EID: 80052137854     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0055     Document Type: Article

References (42)

1. Capurso G, Fazio N, Festa S, Panzuto F, De Braud F & Delle Fave G 2009 Molecular target therapy for gastroenter-opancreatic endocrine tumours: biological rationale and clinical perspectives. Critical Reviews in Oncology/Hematology 72 110-124. (doi:10.1016/j.critrevonc.2009.01.008)
2. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J et al. 2006 Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. Journal of Clinical Oncology 24 4092-4099. (doi:10.1200/JCO.2005.05.3447)
3. Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J, Fisher W, Latz JE, Li X, Wu J et al. 2010 Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. Journal of Thoracic Oncology 5 1815-1820. (doi:10.1097/JTO.0b013e3181ee820c)
4. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y & Blumgart LH 2000 Hepatic neuroendocrine metastases: does intervention alter outcomes? Journal of the American College of Surgeons 190 432-445. (doi:10.1016/S1072-7515(00)00222-2)
5. Cross DA, Alessi DR, Cohen P, Andjelkovich M &Hemmings BA 1995 Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 785-789. (doi:10.1038/378785a0)
6. Ehehalt F, Saeger HD, Schmidt CM & Grützmann R 2009 Neuroendocrine tumors of the pancreas. Oncologist 14 456-467. (doi:10.1634/theoncologist.2008-0259)
7. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR & Mills GB 2002 Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Molecular and Cellular Biology 22 2099-2110. (doi:10.1128/MCB.22.7.2099-2110.2002)
8. Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A & Rothmund M 2006 An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Annals of Surgery 244 845-853. (doi:10.1097/01.sla.0000246951.21252.60)
9. Goekjian PG & Jirousek MR 2001 Protein kinase C inhibitors as novel anticancer drugs. Expert Opinion on Investigational Drugs 10 2117-2140. (doi:10.1517/13543784.10.12.2117)
10. Gong J, Lee J, Akio H, Schlegel PN & Shen R 2007 Attenuation of apoptosis by chromogranin A-induced Akt and survivin pathways in prostate cancer cells. Endocrinology 148 4489-4499. (doi:10.1210/en.2006-1748)
11. Goode N, Hughes K, Woodgett JR & Parker PJ 1992 Differential regulation of glycogen synthase kinase-3 β by protein kinase C isotypes. Journal of Biological Chemistry 267 16878-16882.
12. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE et al. 2005 The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Research 65 7462-7469. (doi:10.1158/0008-5472. CAN-05-0071)
13. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, Salahuddin N, Korbonits M & Grossman AB 2008 Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 87 168-181. (doi:10.1159/000111501)
14. Herbst RS, Thorton DE & Kies MS 2002 Phase I study of LY317615, a protein kinase Cb inhibitor. Proceedings of the American Society of Clinical Oncology 21 82a.
15. Hocevar BA, Burns DJ & Fields AP 1993 Identification of protein kinase C (PKC) phosphorylation sites on human lamin B. Potential role of PKC in nuclear lamina structural dynamics. Journal of BiologicalChemistry 268 7545-7552. (Pubitemid 23105656)
16. Hug H & Sarre TF 1993 Protein kinase C isoenzymes: divergence in signal transduction? Biochemical Journal 291 329-343.
17. Jaken S & Parker PJ 2000 Protein kinase C binding partners. Bioessays 22 245-254. (doi:10.1002/(SICI)1521-1878(200003)22:3〈245::AID- BIES6〉3.0.CO;2-X)
18. Kuo WL, Liu J, Mauceri H, Vokes EE, Weichselbaum R, Rosner MR & Cohen EE 2010 Efficacy of the multikinase inhibitor enzastaurin is dependent on cellular signaling context. Molecular Cancer Therapeutics 9 2814-2824. (doi:10.1158/1535-7163.MCT-10-0352)
19. Mendez CF, Leibiger IB, Leibiger B, Høy M, Gromada J, Berggren PO & Bertorello AM 2003 Rapid association of protein kinase C-epsilon with insulin granules is essential for insulin exocytosis. Journal of Biological Chemistry 278 44753-44757. (doi:10.1074/jbc.M308664200)
20. 2+ channels and regulates chromogranin a secretion in BON-1 cells. Neuroendocrinology 82 87-102. (doi:10.1159/000091008)
21. Miura A, Ishizuka T, Itaya S, Ishizawa M, Kanoh Y, Kimura M, Kajita K & Yasuda K 1998 Glucose- and phorbol ester-induced insulin secretion in human insulinoma cells - association with protein kinase C activation. Biochemistry and Molecular Biology International 46 739-745. (doi:10.1080/15216549800204282)
22. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J et al. 2007 Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 109 4964-4972. (doi:10.1182/blood-2006-10-054577)
23. Murray NR & Fields AP 1998 Phosphatidylglycerol is a physiologic activator of nuclear protein kinase C. Journal of Biological Chemistry 273 11514-11520. (doi:10.1074/jbc.273.19.11514)
24. Musashi M, Ota S & Shiroshita N 2000 The role of protein kinase C isoforms in cell proliferation and apoptosis. International Journal of Hematology 72 12-19.
25. Oberg K, Akerström G, Rindi G & Jelic S 2010 ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21 (Suppl 5) v223-v227. (doi:10.1093/annonc/mdq192)
26. Parekh D, Ishizuka J, Townsend CM Jr, Haber B, Beauchamp RD, Karp G, Kim SW, Rajaraman S, Greeley G Jr &Thompson JC 1994 Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas 9 83-90. (doi:10.1097/00006676-199401000-00013)
27. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D et al. 2001 Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98 428-435. (doi:10.1182/blood.V98.2.428)
28. Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, Sabharwal SS, Krett NL & Rosen ST 2006 The selective protein kinase Cb inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. Journal of Investigative Dermatology 126 1641-1647. (doi:10.1038/sj.jid.5700322)
29. Richards DA, Kuefler PR, Becerra C, Wilfong LS, Gersh RH, Boehm KA, Zhan F, Asmar L, Myrand SP, Hozak RR et al. 2011 Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study. Investigational New Drugs 29 144-153. (doi:10.1007/s10637-009-9307-8)
30. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M et al. 2009 PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/JCO.2009.22.8510)
31. Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL & Rosen ST 2006 Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Molecular Cancer Therapeutics 5 1783-1789. (doi:10.1158/1535-7163.MCT-05-0465)
32. Tagliati F, Zatelli MC, Bottoni A, Piccin D, Luchin A, Culler MD & degli Uberti EC 2006 Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro. Endocrinology 147 3530-3538. (doi:10.1210/en.2005- 1479)
33. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C &Faul M 2001a Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clinical Cancer Research 7 634-640. (Pubitemid 32707989)
34. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C&Faul MM 2001b Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts. Cancer Chemotherapy and Pharmacology 48 473-480. (doi:10.1007/s002800100372)
35. Teicher BA, Menon K, Alvarez E, Shih C & Faul MM 2002 Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts. Investigational New Drugs 20 241-251. (doi:10.1023/A:1016297611825)
36. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G &Seufferlein T 2000 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research 60 4573-4581. (Pubitemid 32103642)
37. Wiegand C & Hipler U 2008 Methods for the measurement of cell and tissue compatibility including tissue regeneration processes. GMS Krankenhaushygiene Interdisziplinär 3 Doc12.
38. Wulbrand U, Remmert G, Zofel P, Wied M, Arnold R &Fehmann HC 2000 mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. European Journal of Clinical Investigation 30 729-739. (doi:10.1046/j.1365-2362.2000.00700.x)
39. Xing N, Qian J, Bostwick D, Bergstralh E & Yong YF 2001 Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 48 7-15. (doi:10.1002/pros.1076)
40. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M & degli Uberti EC 2002 Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochemical and Biophysical Research Communications 297 828-834. (doi:10.1016/S0006-291X(02)02307-0)
41. Zatelli MC, Maffei P, Piccin D, Martini C, Rea F, Rubello D, Margutti A, Culler MD, Sicolo N & degli Uberti EC 2005 Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. Journal of Clinical Endocrinology and Metabolism 90 2104-2109. (doi:10.1210/jc.2004-2156)
42. Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L, degli Uberti EC et al. 2007 Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocrine-Related Cancer 14 473-482. (doi:10.1677/ERC-07-0001)